Cochrane Abstracts
PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"PI3K/AKT/mTOR Inhibitors for Advanced or Recurrent Endometrial Cancer." Cochrane Abstracts, John Wiley & Sons, Inc, 2025. Evidence Central, evidence.unboundmedicine.com/evidence/view/Cochrane/438805/1/PI3K_AKT_mTOR_inhibitors_for_advanced_or_recurrent_endometrial_cancer.
PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer. Cochrane Abstracts. John Wiley & Sons, Inc; 2025. https://evidence.unboundmedicine.com/evidence/view/Cochrane/438805/1/PI3K_AKT_mTOR_inhibitors_for_advanced_or_recurrent_endometrial_cancer. Accessed January 17, 2025.
PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer. (2025). In Cochrane Abstracts. John Wiley & Sons, Inc. https://evidence.unboundmedicine.com/evidence/view/Cochrane/438805/1/PI3K_AKT_mTOR_inhibitors_for_advanced_or_recurrent_endometrial_cancer
PI3K/AKT/mTOR Inhibitors for Advanced or Recurrent Endometrial Cancer [Internet]. In: Cochrane Abstracts. John Wiley & Sons, Inc; 2025. [cited 2025 January 17]. Available from: https://evidence.unboundmedicine.com/evidence/view/Cochrane/438805/1/PI3K_AKT_mTOR_inhibitors_for_advanced_or_recurrent_endometrial_cancer.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer
ID - 438805
BT - Cochrane Abstracts
UR - https://evidence.unboundmedicine.com/evidence/view/Cochrane/438805/1/PI3K_AKT_mTOR_inhibitors_for_advanced_or_recurrent_endometrial_cancer
PB - John Wiley & Sons, Inc
DB - Evidence Central
DP - Unbound Medicine
ER -
